Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
AGEN > SEC Filings for AGEN > Form 8-K on 8-Oct-2013All Recent SEC Filings

Show all filings for AGENUS INC

Form 8-K for AGENUS INC


8-Oct-2013

Other Events, Financial Statements and Exhibits


Item 8.01 Other events

Agenus Inc. announced today that new Phase 3 data for GlaxoSmithKline's (NYSE:
GSK) RTS,S malaria vaccine candidate, which contains Agenus' QS-21 Stimulon® adjuvant, were presented at a Multilateral Initiative on Malaria Pan African Conference in Durban, South Africa. The abstract and presentation titled, "Efficacy of RTS,S/AS01 vaccine candidate against malaria in African infants and children 18 months post-primary vaccination series: a Phase 3 randomized, double-blind controlled trial," shows that RTS,S helped protect young children and infants from clinical malaria up to 18 months post vaccination.

The full text of the press release issued in connection with the announcement is being filed as Exhibit 99.1 to this current report on Form 8-K.



Item 9.01 Financial Statements and Exhibits

(d) Exhibits

The following exhibit is filed herewith:

99.1 Press Release dated October 7, 2013


  Add AGEN to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for AGEN - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.